複雑性尿路感染症に対するKW-1070の使用経験 (KW-1070(FORTIMICIN)<特集>)
スポンサーリンク
概要
- 論文の詳細を見る
1) KW-1070 was administered to 20 patients with complicated urinary tract infections for 5 days at a daily dosage of 600 mg (300mg × 2).<BR>2) The clinical effects of KW-1070 were excellent in 6 cases, moderate in 7 cases and poor in 7 cases. The efficacy rate was 65%.<BR>3) Bacteriological efficacy was 100% against <I>E. coli, Serratia</I>, and <I>Proteus</I>, and 40% against <I>Pseudomonas</I>.<BR>4) The efficacy in urinary tract infections was 57%(4/7) in Group 3 and 69%(9/13) in Group 4.<BR>5) As for the side effects, a slight increase of GOT, GPT and Al-P and slight increase of BUN and creatinine were observed in 2 of the 20 cases. However, two cases recovered normally a few days after administration.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.